|
gptkbp:instanceOf
|
gptkb:drug
gptkb:interferon_beta-1b
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1993
|
|
gptkbp:ATCCode
|
gptkb:L03AB08
|
|
gptkbp:CASNumber
|
105857-23-2
|
|
gptkbp:contraindication
|
severe depression
hepatic impairment
hypersensitivity to interferon beta
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:form
|
powder for solution for injection
|
|
gptkbp:halfLife
|
5 to 8 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Betaferon
|
|
gptkbp:indication
|
gptkb:secondary_progressive_multiple_sclerosis
relapsing-remitting multiple sclerosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bayer
|
|
gptkbp:mechanismOfAction
|
immunomodulation
|
|
gptkbp:otherName
|
gptkb:Betaseron
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:proteinBinding
|
low
|
|
gptkbp:PubChem_CID
|
DB00060
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
injection site reaction
flu-like symptoms
liver enzyme elevation
|
|
gptkbp:UNII
|
GOL4793W7D
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Schering_AG
|
|
gptkbp:bfsLayer
|
7
|